Welcome to the UK Industry Pharmacogenomics Network (UK-IPN)

Driving Industry Collaboration in Pharmacogenomics

The UK Industry Pharmacogenomics Network (UK-IPN) is a pioneering collaborative designed to support and empower the life science industry in advancing pharmacogenomic testing as an integral part of the UK healthcare system. Aligning closely with the NHS Genomics agenda, UK-IPN is committed to fostering partnerships that facilitate the adoption and implementation of pharmacogenomic testing and services, ensuring that commercial organisations become core contributors to national efforts in precision medicine.

Our Mission

UK-IPN brings together companies with a vested interest in pharmacogenomics— whether as manufacturers of medical devices, software solutions, or diagnostic tools—providing a united industry voice to navigate the evolving regulatory landscape and integration pathways within the NHS. By working in partnership with the NHS, government, and regulatory bodies, UK-IPN:

seeks to identify and overcome barriers that may hinder the widespread adoption of pharmacogenomic testing in clinical practice
co-create end-to-end pathways to aid adoption and implementation

Why This Matters

Pharmacogenomics holds enormous potential in transforming patient care by tailoring medication choices based on an individual's genetic profile. As the NHS moves towards embedding genomic medicine into routine care, industry involvement is crucial to ensuring accessible, efficient, and scalable pharmacogenomic solutions that benefit patients nationwide.

UK-IPN champions this transformation by advocating for industry best practices, supporting key regulatory initiatives, and providing a structured forum for dialogue between commercial stakeholders and healthcare leaders.

Our Work & Impact

UK-IPN facilitates collaboration across sectors, supporting strategic engagement with NHS leaders, contributing to key projects such as the UK Regulatory Science and Innovation Network in Pharmacogenomics, and working collectively to enhance the visibility, trust and reputation of commercial pharmacogenomics within the UK healthcare system. Through active participation in regulatory discussions, adherence to industry codes of conduct, and a commitment to improving patient outcomes, UK-IPN strives to embed pharmacogenomics as standard care across the NHS.

Art of the Possible in Pharmacogenomics

The UK-IPN is not just about collaboration; it's about envisioning and realising the art of the possible in pharmacogenomics. By bringing together industry leaders, healthcare professionals, and regulatory bodies, we are pushing the boundaries of what can be achieved in personalised medicine. This collaborative effort is transforming patient care by tailoring medication choices based on an individual's genetic profile, ensuring that the future of healthcare is not just a possibility, but a reality.

Join Us